Literature DB >> 19059336

Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Rebecca Banerjee1, Anatoly A Starkov, M Flint Beal, Bobby Thomas.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder with unknown etiology. It is marked by widespread neurodegeneration in the brain with profound loss of A9 midbrain dopaminergic neurons in substantia nigra pars compacta. Several theories of biochemical abnormalities have been linked to pathogenesis of PD of which mitochondrial dysfunction due to an impairment of mitochondrial complex I and subsequent oxidative stress seems to take the center stage in experimental models of PD and in postmortem tissues of sporadic forms of illness. Recent identification of specific gene mutations and their influence on mitochondrial functions has further reinforced the relevance of mitochondrial abnormalities in disease pathogenesis. In both sporadic and familial forms of PD abnormal mitochondrial paradigms associated with disease include impaired functioning of the mitochondrial electron transport chain, aging associated damage to mitochondrial DNA, impaired calcium buffering, and anomalies in mitochondrial morphology and dynamics. Here we provide an overview of specific mitochondrial functions affected in sporadic and familial PD that play a role in disease pathogenesis. We propose to utilize these gained insights to further streamline and focus the research to better understand mitochondria's role in disease development and exploit potential mitochondrial targets for therapeutic interventions in PD pathogenesis.

Entities:  

Mesh:

Year:  2008        PMID: 19059336      PMCID: PMC2867353          DOI: 10.1016/j.bbadis.2008.11.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  228 in total

Review 1.  Epidemiology of Parkinson's disease.

Authors:  C M Tanner; Y Ben-Shlomo
Journal:  Adv Neurol       Date:  1999

2.  Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family.

Authors:  R H Swerdlow; J K Parks; J N Davis; D S Cassarino; P A Trimmer; L J Currie; J Dougherty; W S Bridges; J P Bennett; G F Wooten; W D Parker
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

3.  Mitochondrial ND5 mutations in idiopathic Parkinson's disease.

Authors:  W Davis Parker; Janice K Parks
Journal:  Biochem Biophys Res Commun       Date:  2005-01-21       Impact factor: 3.575

4.  Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.

Authors:  Darren J Moore; Li Zhang; Juan Troncoso; Michael K Lee; Nobutaka Hattori; Yoshikuni Mizuno; Ted M Dawson; Valina L Dawson
Journal:  Hum Mol Genet       Date:  2004-11-03       Impact factor: 6.150

5.  Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease.

Authors:  Jan-Willem Taanman; Anthony H V Schapira
Journal:  Neurosci Lett       Date:  2004-12-08       Impact factor: 3.046

Review 6.  Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

Authors:  Moussa B H Youdim; Orit Bar Am; Merav Yogev-Falach; Orly Weinreb; Wakako Maruyama; Makato Naoi; Tamar Amit
Journal:  J Neurosci Res       Date:  2005 Jan 1-15       Impact factor: 4.164

7.  The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism.

Authors:  D S Cassarino; J K Parks; W D Parker; J P Bennett
Journal:  Biochim Biophys Acta       Date:  1999-01-06

8.  Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells.

Authors:  T Minamikawa; D A Williams; D N Bowser; P Nagley
Journal:  Exp Cell Res       Date:  1999-01-10       Impact factor: 3.905

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  90 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 3.  Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.

Authors:  Paul A Lapchak
Journal:  Expert Rev Med Devices       Date:  2012-01       Impact factor: 3.166

Review 4.  Somatic mutations in aging, cancer and neurodegeneration.

Authors:  Scott R Kennedy; Lawrence A Loeb; Alan J Herr
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

5.  Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease.

Authors:  Muhammad Zahid; Muhammad Saeed; Li Yang; Cheryl Beseler; Eleanor Rogan; Ercole L Cavalieri
Journal:  IUBMB Life       Date:  2011-11-02       Impact factor: 3.885

6.  Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+).

Authors:  Francisco J Gómez; Pabla Aguirre; Christian Gonzalez-Billault; Marco T Núñez
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

7.  Negative Conditioning of Mitochondrial Dysfunction in Age-related Neurodegenerative Diseases.

Authors:  Sharmelee Selvaraji; Luting Poh; Venkateswaran Natarajan; Karthik Mallilankaraman; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-02

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 9.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 10.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.